RPL17 and cancer: Of the 87 significantly modulated metabolites in our study, 30 metabolites were found to be common between our study and previously reported HSD serum metabolites profile, 18 metabolites were found to be common in our study and previously published literature on markers for cancer therapeutics, 7 metabolites were found to be common between our study and recently published study of responders of anti-PD1 cancer-therapy in human with the R metabolite profile, and 1 metabolite, hippurate, was uniquely common in all the groups as indicated (Fig. 3G).